Mental Disorders
643 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Narrower: [OBSOLETE] Disordered Eating Behavior 1, Adjustment Disorders 1, Affective Disorders, Psychotic 2, Agoraphobia 1, Alcohol-Related Disorders 23, Alcoholism 22, Alzheimer Disease 94, Anorexia Nervosa 1, Antisocial Personality Disorder 2, Anxiety Disorders 48, Aphasia, Primary Progressive 1, Asperger Syndrome 1, Attention Deficit Disorder with Hyperactivity 8, Autism Spectrum Disorder 14, Autistic Disorder 5, Binge-Eating Disorder 2, Bipolar Disorder 34, Body Dysmorphic Disorders 1, Borderline Personality Disorder 4, Cocaine-Related Disorders 5, Cognition Disorders 43, Cognitive Dysfunction 34, Combat Disorders 13, Dementia 110, Depressive Disorder 193, Depressive Disorder, Treatment-Resistant 44, Dissociative Disorders 1, Dysthymic Disorder 1, Encopresis 1, Erectile Dysfunction 5, Feeding and Eating Disorders 5, Gambling 1, Generalized Anxiety Disorder 8, Huntington Disease 7, Lewy Body Disease 3, Major Depressive Disorder 119, Marijuana Abuse 3, Marijuana Use 1, Neurodevelopmental Disorders 24, Obsessive-Compulsive Disorder 5, Opioid-Related Disorders 19, Panic Disorder 1, Phobia, Social 5, Pick Disease of the Brain 1, Psychological Trauma 1, Psychotic Disorders 16, Schizophrenia 27, Schizophrenia, Childhood 1, Schizophrenia, Treatment-Resistant 1, Seasonal Affective Disorder 1, Sexual Dysfunctions, Psychological 13, Stress Disorders, Post-Traumatic 43, Stress Disorders, Traumatic, Acute 2, Substance-Related Disorders 64, Tobacco Use Disorder 6
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) + Placebo for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) + Placebo for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| [F-18]Flornaptitril for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 100 mg for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 40 Hz sound stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 40 Hz Synchronous Audio-Visual Stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 50 mg qhs for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AADvac1 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AADvac1 for pick disease of the brain | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AB-1001 Gene Therapy for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Abbott Laboratories Infinity™ implantable deep brain stimulation system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Academic Competency Enhancement (ACE) classroom for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Accelerated protocol of home Transcranial direct current stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Accelerated theta-burst stimulation treatment for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Accelerated theta-burst stimulation treatment for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acceptance and Commitment Therapy + Ketamine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acceptance-Based Behavior Therapy (ABBT) for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acetylcysteinamide for dementia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Activa Tremor Control Sys (DBS Implant) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Activa Tremor Control Sys (DBS Implant) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active - Conventional tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active - HD tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| active rTMS treatment for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| active rTMS treatment for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| active tDCS + mindfulness meditation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| active tDCS stimulating left DLPFC for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active tDCS with Sternberg task for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active tDCS with Sternberg task for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active transcranial direct current stimulation for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active Whole-Body Hyperthermia (Active WBH) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acupuncture for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| acupuncture (strong reaction acupoints) + SSRIs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| acupuncture (weak reaction acupoints) + SSRIs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| acupuncture + placebo for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| acupuncture + SSRIs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| acupuncture and moxibustion for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD04 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD5-NCOV for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Administer Leqemi 10 mg/kg, every two weeks. for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aducanumab for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Aducanumab for cognitive dysfunction | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aerobic exercise intervention for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aia for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ambroxol for dementia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ambroxol hydrochloride for lewy body disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amygdala neurofeedback for borderline personality disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| App AURORA (Digital Therapy) + conventional treatment for generalized anxiety disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Arbaclofen for autism spectrum disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aripiprazole for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aripiprazole for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Aripiprazole for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aripiprazole for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Aripiprazole + IEM (Ingestible Event Marker) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aripiprazole + IEM (Ingestible Event Marker) for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Art and physical activity program. for anxiety disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aticaprant for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| ATTN201 Focused Ultrasound to the CMN for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATTN201 Focused Ultrasound to the CMN for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atuzaginstat for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Audiovisual stimulation VR system for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Audiovisual stimulation VR system for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Auricular Acupuncture for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azetukalner for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Baclofen for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Baclofen for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BBB opening for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Behavioral Activation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Behavioural Activation (BA) Therapy for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Behavioural Activation (BA) Therapy for depressive disorder, treatment-resistant | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Behavioural Activation (BA) Therapy for major depressive disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benzocaine Gel applied to the cervix + Hydroxyzine Hydrochloride for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bexicaserin for neurodevelopmental disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bilateral implantation of DBS system to Habeluna for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood Brain Barrier (BBB) Disruption for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Blue-depleted evening light condition for mental disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BPL-003 for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Brenipatide for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Brenipatide for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief Cognitive Behavioral Conjoint Therapy (bCBCT) + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief cognitive task-based intervention for psychological trauma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief cognitive task-based intervention for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief Negotiation Interview for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief Negotiation Interview + Naltrexone + Gabapentin for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buntanetap for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buntanetap tartrate for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Buntanetap tartrate for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bupropion + Escitalopram + Venlafaxine + SERTRALINE for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bupropion + Escitalopram + Venlafaxine + SERTRALINE for major depressive disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bupropion + Escitalopram + Venlafaxine + SERTRALINE for schizophrenia | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cabotegravir for substance-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cal-Mag Butyrate for cognition disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for marijuana abuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol + Dronabinol for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet + Naproxen 500 Mg + Opioids for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CBCT + Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cca for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cervical Lymphatic Microsurgery for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chlorhexidine for erectile dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cholecalciferol for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cholecalciferol for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| chronobiological augmentation for bipolar disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| chronobiological augmentation for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI-581a for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI/BNST stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI/BNST stimulation + ITP Stimulation + No stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI/BNST stimulation + No stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clinical assessment + salivary collections of amylase and cortisol + Stress elicitation experiment + Structural and Functional MRI for borderline personality disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clozapine for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clozapine for major depressive disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clozapine for schizophrenia | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Behavioral Therapy (CBT) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Behavioral Therapy (CBT) + Whole-Body Hyperthermia for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Behavioral Therapy (CBT) + Whole-Body Hyperthermia (WBH) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Behavioral Therapy + Psilocybin for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Processing Therapy for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive task + Left DLPFC tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive task + Right DLPFC tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Training for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cognitive Training + Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for encopresis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined LAI Treatment: Cabenuva and Sublocade for opioid-related disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined metabolic activators for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for aphasia, primary progressive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Contingency management for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Biospecimen Collection + Interview + Survey Administration + Psilocybin for depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Quitting using Medication for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Switching to E-Cigarette for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Crisugabalin for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Curcumin for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Curcumin and Fluoxetine for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclobenzaprine hydrochloride for stress disorders, traumatic, acute | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| D-Cycloserine (DCS) for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| D-Cycloserine (DCS) for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Daoib for dementia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Daridorexant for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dbs for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dbs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DBS + No Stimulation (Sham) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DBS of the NAc for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DBS system for obsessive-compulsive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DC-LVA treatment plus usual care for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Simulator for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for anorexia nervosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for autistic disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for gambling | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Deep Brain Stimulation for obsessive-compulsive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Deep Brain Stimulation for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation (DBS) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation Model 3387 Model 3389 for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation Model 3387 Model 3389 for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| deep brain stimulation with short & long pulse width for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| deep brain stimulation with short & long pulse width for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| deep brain stimulation with short & long pulse width for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation, DBS for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation, implanted for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep brain stimulation(Active) + Deep brain stimulation(Sham) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep brain stimulation(Active) + Deep brain stimulation(Sham) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation(DBS) + Esketamine for depressive disorder, treatment-resistant | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymph node to venous bypass (DCLNV-BP) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphatic-venous anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphatic-venous anastomosis, LVA for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for lewy body disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical lymphatlc-Venous Anastomosis Surgery for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphovenous anastomosis (LVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphovenous Anastomosis + Routine Treatment for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphovenous Anastomosis + Routine Treatment for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device-only fitting for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device-only fitting for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device: Directional Deep Brain Stimulation for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexmedetomidine hydrochloride for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexmedetomidine hydrochloride for stress disorders, traumatic, acute | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dextromethorphan and Bupropion Sustained-Release Tablets for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diamorphine hydrochloride anhydrous for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dietary vitamin D for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dimethyltryptamine for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Divalproex sodium for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Donanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Donanemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Donanemab for lewy body disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + 2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy- for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + Dexamethasone for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + Nivegacetor for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Double Active: Active portable transcranial stimulation (ptES) and active internet-based behavioral therapy (iBT) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dronabinol for marijuana abuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DTT106 for erectile dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DynamiCare Health for opioid-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| E-Cigarette 7.2 mg nicotine for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EB-1020 (Centanafadine) high dose for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EB-1020 (Centanafadine) low dose for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ecig 24 mg nicotine for schizophrenia | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| edupression.com® for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| edupression.com® for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EEG-based personalized TMS for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Electroacupuncture for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Electroacupuncture for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| electronic cigarette for tobacco use disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elunetirom for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emestedastat for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emono for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emraclidine for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Endd (njoy) for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Escitalopram + Esketamine + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Esketamine for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Esketamine for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for schizophrenia | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esketamine Treatment as Usual (ESK) + Virtual-Reality-based mindfulness intervention for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esketamine Treatment as Usual (ESK) + Virtual-Reality-based mindfulness intervention for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esomeprazole for autistic disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Estradiol for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Etanercept for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evenamide 15 mg bid for schizophrenia, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ExAblate 4000 Type 2.1 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exercise + Control for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Experimental regimen for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Facilitate tDCS + CR for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Facilitate tDCS + CR for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Facilitate tDCS + CR for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fasedienol for phobia, social | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Fasudil for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fasudil for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplant (FMT) for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplant (FMT) + Vancomycin + NITAZOXANIDE for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Flibanserin for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 11 |
| FLUOROETHOXYBENZOVESAMICOL F-18 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Fluoxetine for obsessive-compulsive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine + Dextromethorphan for body dysmorphic disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine + Dextromethorphan for obsessive-compulsive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine + Imipramine for dysthymic disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine + Imipramine for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Full Dose Midomafetamine HCl for stress disorders, post-traumatic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gam-COVID-Vac for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GammaSense Stimulation device for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gantenerumab for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| GENUS device (Active Settings) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GENUS device (Active Settings) for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ginkgo for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + naltrexone and bupropion (combination) for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + naltrexone and bupropion (combination) for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Phentermine-Topiramate for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Phentermine-Topiramate for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Semaglutide for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Semaglutide for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GV-971 for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| GV-971 + MEMANTINE for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GXV-813 for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hatha Yoga Practice Group for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HB-1 for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Healthy Activity Program (HAP) for depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Heart to Heart Yoga for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High intensity whole-body infrared heating for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| High Monetary Incentive (HMI) + Message-Based Psychotherapy (MBP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High Monetary Incentive (HMI) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High Monetary Incentive (HMI) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High Monetary Incentive (HMI) + Video-Chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High THC Cannabis for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High THC Cannabis for marijuana abuse | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High THC Cannabis for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity inpatient MDMA-assisted psychotherapy for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HS-10380 for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hUC-MSC-Exos Nasal Spray for autism spectrum disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| human Mesenchymal Stem Cells for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| human Mesenchymal Stem Cells for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxyzine Hydrochloride for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxyzine Hydrochloride + Lidocaine for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hyperbaric Oxygen Therapy for combat disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ibogaine hydrochloride for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Iclepertin for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Increasing control over stimulant use and physical health through incentivized rehabilitation for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Individualized rTMS (transcranial magnetic stimulation) for depressive disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Integration Therapy for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Integration Therapy for dissociative disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intra-striatal rAAV5-miHTT for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| intracavernous platelet rich plasma therapy for erectile dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ITI-1284 10 mg for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ITI-1284 20 mg for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ITP Stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JNJ-64042056 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarX-EC + KarXT for autism spectrum disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarX-EC + KarXT for autistic disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarX-EC + KarXT for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarXT for autistic disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarXT for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ketamine for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ketamine for stress disorders, post-traumatic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for alcoholism | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for stress disorders, post-traumatic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine-Assisted Psychotherapy (KAP) for anxiety disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine-Assisted Psychotherapy (KAP) for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ketogenic Diet for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ketogenic Diet for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ketogenic Diet for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet + Non-ketogenic Diet for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic diet intervention for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic diet intervention for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic foodstuffs for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Therapy for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| kudzu extract, puerarin for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lacosamide for bipolar disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LCHF Ketogenic Diet for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lecanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Lecanemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| LECANEMAB + Etalanetug for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Left DLPFC tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for asperger syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Leucovorin for autistic disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Levoleucovorin calcium for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lifus for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| light box + Wake Therapy + LITHIUM for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| light box + Wake Therapy + LITHIUM for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lithium for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Lithium carbonate + perospirone hydrochloride for depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lithium sulphate prolonged-release 660 mg for bipolar disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| low intensity focused ultrasound (LIFU) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy (MBP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Monetary and Alternative Incentive (LMAI) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low Monetary and Alternative Incentive (LMAI) + Video-Chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-intensity focused ultrasound for cocaine-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-intensity focused ultrasound for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-Intensity Focused Ultrasound + Low-Intensity Focused Ultrasound - sham for anxiety disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-Intensity Focused Ultrasound + Low-Intensity Focused Ultrasound - sham for opioid-related disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lurasidone for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY-2599666 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY-2599666 for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813 for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813-IV for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813-SC for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lysergide d-tartrate for attention deficit disorder with hyperactivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lysergide d-tartrate for generalized anxiety disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Mad for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnesium for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Manualized therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Manualized therapy + Midomafetamine HCl for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matched Placebo (oral gummy) + Δ9-Tetrahydrocannabivarin (oral gummy) for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Intramuscular Placebo + IBOGAINE HYDROCHLORIDE for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo (E2814) + LECANEMAB for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDMA Assisted Therapy for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDMA Assisted Therapy for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mdma-at for combat disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mdma-at for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Activa PC+S System for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Activa SC DBS, Lead Model 3387 for depressive disorder, treatment-resistant | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Percept PC DBS system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Percept PC DBS system for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic SenSight Directional DBS lead for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Summit RC+S DBS system for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Medtronic Summit RC+S DBS system for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Memantine for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| MEOPA (Nitrous Oxide/Oxygen Premix) for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-based psychotherapy (MBP) for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-based psychotherapy (MBP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-Based Psychotherapy (MBP) + Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-Based Psychotherapy (MBP) + Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy + Video-Chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy + Video-Chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin hydrochloride for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Methylphenidate hydrochloride for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Methylphenidate hydrochloride for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mevidalen for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midazolam Placebo Solution + Esketamine for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine for adjustment disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Midomafetamine for combat disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 18 |
| Midomafetamine for substance-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine HCl for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Midomafetamine Hydrochloride for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-Based Stress Reduction for agoraphobia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-Based Stress Reduction for generalized anxiety disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-Based Stress Reduction for panic disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-Based Stress Reduction for phobia, social | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindfulness-centered psilocybin-assisted therapy + Music-centered psilocybin-assisted therapy + Psilocybin for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindset for alcohol-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MK-1167 for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| ML-007C-MA for psychotic disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ML-007C-MA for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Moderate doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Modified deep cervical Lymphatic-Venous Anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MR guided low intensity focused ultrasound for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Music & Auditory Beat Stimulation for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Music and Theta Auditory Beat Stimulation for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Music Therapy for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NanoLithium® NP03 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for affective disorders, psychotic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for schizophrenia, childhood | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NBI-1117570 for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Next Generation Dome Helmet (NGDH) for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide Riboside (NR) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide Riboside (NR) for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nightmare Deconstruction and Reprocessing for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NightWare for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| NightWare smartwatch configured to detect physiological signs of sympathetic activation during sleep, such as heart-rate spikes and movement patterns. for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NightWare Therapeutic System for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| NightWare Therapeutic System for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Nitrous Oxide for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Nitrous Oxide for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Nivegacetor for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nmdae for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nmdae for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NMDAE plus AIFA for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NMS-01 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Obicetrapib 10 mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oculus VR headset for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olanzapine for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olanzapine and Fluoxetine combination (OFC) for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olz/sam for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| omega-3 for antisocial personality disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Omega-3 supplemented drink for antisocial personality disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| one night of sleep deprivation and two FDG PET scans for bipolar disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| one night of sleep deprivation and two FDG PET scans for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ORG-34517 for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OT-led Exercise Group for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxcarbazepine for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxytocin for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pemvidutide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Perospirone hydrochloride tablets for depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PHEN/TPM ER (Qsymia®) for binge-eating disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for schizophrenia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + ADUCANUMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Placebo + ADUCANUMAB for cognitive dysfunction | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Donanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Escitalopram + Venlafaxine + Duloxetine + SERTRALINE for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Nimodipine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Psilocybin for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Psilocybin + Propofol for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + SRP-1005 for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| placebo 2 tablets qhs for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo Nasal Spray for phobia, social | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Placebo Nasal Spray - Placebo Nasal Spray for phobia, social | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo of trazodone + Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prolonged Exposure + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prolonged exposure therapy + MIDOMAFETAMINE for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prolonged exposure therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Propranolol for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Propranolol for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psa for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 8 |
| Psilocybin for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Psilocybin for bipolar disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for borderline personality disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for cocaine-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 8 |
| Psilocybin for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 19 |
| Psilocybin for obsessive-compulsive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Psilocybin for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Psilocybin + MBCT therapy for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + Modafinil for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + PIMAVANSERIN for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + PIMAVANSERIN + Modafinil for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + Placebo for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + ZOLPIDEM for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + ZOLPIDEM + Modafinil for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + ZOLPIDEM + PIMAVANSERIN for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + ZOLPIDEM + PIMAVANSERIN + Modafinil for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychopharmacological treatment for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + Medication for opioid use disorder for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + MIDOMAFETAMINE for combat disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psychotherapy + Survey Administration + Psilocybin for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Questionnaires for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Questionnaires for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Quetiapine for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Randomized, staggered withdrawal phase for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Randomized, staggered withdrawal phase for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| real-time fMRI neurofeedback training for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| real-time fMRI neurofeedback training + Ketamine for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for dementia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters) for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters) for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relapse prevention cognitive behavioral therapy (CBT) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| REPAIR Sleep for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| REPAIR Sleep for cognition disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RGH-202 for phobia, social | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Right DLPFC tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Risperidone for psychotic disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Risperidone for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Rituximab for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP902 for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rTMS treatment + Ketamine for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S1B-408 for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Saccharomyces cerevisiae for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sea-it for combat disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sea-it for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semagludtide for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Sense4Safety for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sertraline for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| sertraline, lithium for bipolar disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| sertraline, lithium for major depressive disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Service-only Fitting for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Service-only Fitting for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| sex therapy + Flibanserin for sexual dysfunctions, psychological | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SGB - Combined Solution of Bupivacaine + Ketamine Adjuvant for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| sham acupuncture + SSRIs for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Sham neurofeedback for borderline personality disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Shuganjieyu capsule for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simple cognitive task for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Simufilam for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| SmartSleep EEG recording headband + Ketamine for stress disorders, post-traumatic | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium lactate for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 600mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 600mg for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 900mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 900mg for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium Oligomannate Capsules for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solanezumab for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Solanezumab for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solizmestrocel for erectile dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solriamfetol for binge-eating disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPT-300 for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPT-300 for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SSRI/SNRI + Esketamine for depressive disorder, treatment-resistant | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SSRI/SNRI + Esketamine for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| STAM 1100mAh CE4 eGo Clearomizer for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Standardized kudzu for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Step count goal for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stimulation-ON for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured Integrated Reframing Therapy (SIRT) for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured Integrated Reframing Therapy (SIRT) for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured Integrated Reframing Therapy (SIRT) + Psilocybin for major depressive disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured Integrated Reframing Therapy (SIRT) + Psilocybin for stress disorders, post-traumatic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Supermicrosurgical Lymphaticovenular Anastomosis (LVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Supportive psychotherapy + Psilocybin for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Supportive psychotherapy + Psilocybin + MICROCRYSTALLINE CELLULOSE for major depressive disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tACS combined with 40 Hz sound stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Task-oriented resistance exercise for cognitive dysfunction | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAU+CBT for pts+Family Intervention+CM. for affective disorders, psychotic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAU+CBT for pts+Family Intervention+CM. for psychotic disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tDCS for depressive disorder, treatment-resistant | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| tDCS for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| TDCS - transcranial direct current stimulation for anxiety disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tDCS (Eldith DC-Stimulator (CE certified)) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| tDCS over DLPFC for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tDCS over DLPFC for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Testosterone undecanoate for sexual dysfunctions, psychological | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Therabot for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Therabot for feeding and eating disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Therapy + MIDOMAFETAMINE for stress disorders, post-traumatic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Tirzepatide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Tominersen for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Transcranial alternating current stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial Direct Current Stimulation for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| transcranial direct current stimulation (tDCS) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial direct current stimulation (tDCS) on the Left DLPFC for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial direct current stimulation (tDCS) on the right VLPFC for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial Direct Current Stimulation + SERTRALINE for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| transcranial magnetic resonance guided focused ultrasound BBB disruption for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trazodone 5mg + Psilocybin for depressive disorder, treatment-resistant | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TREATMENT ARM: Full dose for combat disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TREATMENT ARM: Full dose for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Ketone Supplement for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Placebo for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tributyrin for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tributyrin for cognitive dysfunction | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Troculeucel for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trontinemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Trontinemab for cognitive dysfunction | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tsa for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TTYP01 Tablets (12mg or 18mg) for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ulotaront for schizophrenia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Umblical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes for erectile dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valacyclovir for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valacyclovir for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valiltramiprosate for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valproic acid for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Vancomycin + NITAZOXANIDE for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Varenicline for marijuana use | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Varenicline for tobacco use disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Venlafaxine for generalized anxiety disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vericiguat for cognitive dysfunction | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Video-chat Psychotherapy (VCP) for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Video-chat Psychotherapy (VCP) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Viloxazine hydrochloride for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Visuospatial Task (VST) for stress disorders, post-traumatic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin d for seasonal affective disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin D 100 micrograms for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Votoplam (blinded) for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VR social musical exergame for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VR solo musical exergame for anxiety disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Walk-and-talk therapy for anxiety disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wbh for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Whole-Body Hyperthermia for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Whole-Body Hyperthermia for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Whole-body hyperthermia + standard medical care for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wujia Yizhi granules for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wysa Digital Chatbot Program for [obsolete] disordered eating behavior | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xanomeline Enteric Capsule + Xanomeline/Trospium Chloride Capsule for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xiaochaihu Granules (Low Dose) for depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xingqi Daozhi Decoction for schizophrenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Yband(YDT-201N) for major depressive disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ziprasidone for bipolar disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zonisamide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.